Vanguard Personalized Indexing Management
ACRS icon

Vanguard Personalized Indexing Management’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83K Sell
15,691
-1,867
-11% -$8.33K ﹤0.01% 2078
2026
Q1 		$65.8K Buy
+17,558
New +$59.2K ﹤0.01% 2016

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Personalized Indexing Management's ACRS Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its Aclaris Therapeutics (ACRS) stake by 11% in Q2 2026, selling an estimated $8.33K and leaving 15,691 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Vanguard Personalized Indexing Management first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Vanguard Personalized Indexing Management held 15,691 shares of Aclaris Therapeutics worth $83K as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 1,867 Aclaris Therapeutics shares in Q2 2026, an estimated $8.33K.
  • Aclaris Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #2078 holding.
  • Vanguard Personalized Indexing Management first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.